Form 4: Boston Scientific CEO Michael Mahoney Reports Stock Transaction

Boston Scientific's CEO, Michael Mahoney, reported a transaction involving the disposal of 7,800 shares of common stock held in trust.

Summary

• Michael Mahoney, the Chairman, President, and CEO of Boston Scientific, filed a Form 4 indicating a change in his beneficial ownership of the company's stock.
• On November 26, 2024, Mr. Mahoney disposed of 7,800 shares of common stock at a price of $0.00 per share.
• These shares were held indirectly through a trust.
• Following the transaction, Mr. Mahoney's total beneficial ownership includes 1,521,205 shares held directly and 201,478 shares held indirectly through a trust.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting a routine transaction by a company executive. There is no positive or negative sentiment associated with the filing itself.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company executive, which is common in the corporate world.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders and are required by the SEC to ensure transparency in stock transactions.
• The transaction is not unusual for a CEO and is similar to filings made by executives at comparable companies such as Medtronic (MDT) and Abbott Laboratories (ABT).

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a routine filing related to executive stock ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transaction, Boston Scientific, Michael Mahoney, BSX, SEC Filing